We are live on ! Find out more
AA

AlphaCentric Advisors Portfolio holdings

AUM $100M
This Fund
S&P 500
This Quarter Est. Return
+1.31%
1 Year Est. Return
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$100M
AUM Growth
-$233K
Cap. Flow
+$2.63M
Cap. Flow %
2.63%
Top 10 Hldgs %
20.23%
Holding
305
New
56
Increased
128
Reduced
51
Closed
53

Sector Composition

Rank Sector Weight
1 Healthcare 42.59%
2 Industrials 10.06%
3 Real Estate 8.71%
4 Technology 8.48%
5 Financials 5.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
GILD icon
1
Gilead Sciences
GILD
$167B
$2.82M 2.82%
20,260
-1,501
-7% -$210K
RPV icon
2
Invesco S&P 500 Pure Value ETF
RPV
$1.58B
$2.56M 2.56%
23,882
+6,673
+39% +$725K
IWD icon
3
iShares Russell 1000 Value ETF
IWD
$81.9B
$2.53M 2.52%
11,825
+3,418
+41% +$749K
AZN icon
4
AstraZeneca
AZN
$262B
$2.22M 2.21%
11,232
+610
+6% +$118K
VRTX icon
5
Vertex Pharmaceuticals
VRTX
$123B
$2.2M 2.2%
4,931
+268
+6% +$125K
EEFT icon
6
Euronet Worldwide
EEFT
$3.1B
$1.85M 1.85%
27,855
INVH icon
7
Invitation Homes
INVH
$17.9B
$1.81M 1.81%
73,000
-17,000
-19% -$445K
IONS icon
8
Ionis Pharmaceuticals
IONS
$8.99B
$1.47M 1.47%
19,587
+1,064
+6% +$84K
INSM icon
9
Insmed
INSM
$23.5B
$1.45M 1.45%
8,874
+1,286
+17% +$198K
INCY icon
10
Incyte
INCY
$23.4B
$1.34M 1.34%
14,245
+774
+6% +$77.2K
ROIV icon
11
Roivant Sciences
ROIV
$24.8B
$1.32M 1.32%
47,667
+2,591
+6% +$66.6K
ARGX icon
12
argenx
ARGX
$53.8B
$1.31M 1.31%
1,794
+369
+26% +$289K
NBIX icon
13
Neurocrine Biosciences
NBIX
$17.2B
$1.27M 1.26%
9,607
+2,224
+30% +$295K
AXR icon
14
AMREP Corp
AXR
$136M
$1.25M 1.25%
44,496
-20,504
-32% -$486K
BFS
15
Saul Centers
BFS
$899M
$1.14M 1.14%
35,000
+5,000
+17% +$166K
STXS icon
16
Stereotaxis
STXS
$154M
$1.1M 1.1%
600,000
AXSM icon
17
Axsome Therapeutics
AXSM
$11.8B
$1.09M 1.09%
6,438
+350
+6% +$60.5K
ASND icon
18
Ascendis Pharma A/S
ASND
$17.1B
$1.04M 1.03%
4,526
+1,288
+40% +$289K
AMPX icon
19
Amprius Technologies
AMPX
$1.44B
$1.01M 1.01%
60,000
+10,000
+20% +$130K
APGE icon
20
Apogee Therapeutics
APGE
$10.1B
$957K 0.96%
11,369
+618
+6% +$44.9K
PTGX icon
21
Protagonist Therapeutics
PTGX
$9.06B
$953K 0.95%
9,040
+491
+6% +$43.5K
CTO
22
CTO Realty Growth
CTO
$751M
$932K 0.93%
50,400
+5,400
+12% +$101K
SMA
23
SmartStop Self Storage REIT
SMA
$1.9B
$908K 0.91%
30,000
+10,000
+50% +$321K
BLDR icon
24
Builders FirstSource
BLDR
$7.99B
$823K 0.82%
+10,000
New +$1.07M
AMGN icon
25
Amgen
AMGN
$198B
$819K 0.82%
2,329
+127
+6% +$45.3K

Similar funds

AlphaCentric Advisors's Q1 2026 Portfolio in Review

As of Q1 2026, AlphaCentric Advisors held 305 positions worth $100M, down 0.23% from $100M the previous quarter. Its ten largest holdings account for 20% of the portfolio.

AlphaCentric Advisors's Q1 2026 filing shows 56 new, 128 increased, 51 reduced and 53 closed positions. Its largest new stake was Builders FirstSource: 10,000 shares worth $823K. The largest sale was iShares MBS ETF, an estimated $2.48M.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, up from 41% a quarter earlier, followed by Industrials and Real Estate.

  • AlphaCentric Advisors's largest Q1 2026 buy was Builders FirstSource: 10,000 shares worth $823K.
  • AlphaCentric Advisors added most to iShares Russell 1000 Value ETF in Q1 2026, an estimated $749K increase.
  • AlphaCentric Advisors's biggest Q1 2026 reduction was AMREP Corp, cutting an estimated $486K.
  • AlphaCentric Advisors fully exited iShares MBS ETF in Q1 2026, selling an estimated $2.48M.
  • AlphaCentric Advisors's ten largest holdings make up 20% of its $100M portfolio in Q1 2026.
  • AlphaCentric Advisors opened 56 new positions and closed 53 in Q1 2026.
  • AlphaCentric Advisors's portfolio value fell 0.23% quarter-over-quarter to $100M.

Based on AlphaCentric Advisors's 13F filing for Q1 2026, filed 7 May 2026.